The AIM-HI Accelerator Fund (AIM-HI) is an independent 501(C)(3) non-profit organization, established in 2019 with an initial grant from the National Foundation for Cancer Research, with the purpose to accelerate the translation of cancer drug discoveries by investing in seed-stage companies.
The AIM-HI Women’s Venture Competition is a first-of-its-kind initiative combining extensive opportunities for coaching, networking and financial resources exclusively to female-created and managed oncology start-ups. Subject to due diligence and negotiation, the winning business of 2021 Women’s Venture Competition will receive a total of $1 million in investment led by AIM-HI.
NFCR is proud to be a partner organization for this event, helping to support and amplify the contributions of women in the field of oncology. Help us to support oncology start-ups with a DONATION toward early seed money! Your donations will double the impact we can make together to move forward on the path to clinical trails that will eventually save lives!
2020 Women’s Venture Competition Winner
Manijeh Goldberg, Ph.D.
Privo Technologies has received investment of $900,000 – $300,000 from AIM-HI and matching investment from two supporters of the Competition! Read the press release.
Based in Peabody, Massachusetts, the company has developed a nano-engineered platform for redesigning the mechanism of action of potent cancer medicines. For more information, visit https://www.privotechnologies.com.